![Figure 1. CD38 is involved in mMDDC chemotaxis and migration. Lymphoid organ–derived CCL21-driven chemotaxis (A) and transendothelial migration (B) of mMDDCs. (A) LPS-matured MDDCs (1.25 × 105; LPS) were added to the transwell upper chamber in the presence of the indicated stimuli: blocking anti-CD38 mAb (AT13/5), agonistic anti-CD38 mAbs (IB4 and AT2), anti-CD31 mAb (Moon-1), 8-Br-cADPR, or irrelevant control mAb (Ctr mAb). Results are expressed as percentage of migrated cells with respect to migration of LPS-matured MDDCs (28.7% ± 5.3% of the cell input) and are the mean values ± SE of 5 independent experiments. Statistically significant differences (P < .05) with respect to LPS-induced migration are indicated. (B) HPMEC-ST1.6R cells (4 × 105) were grown to confluence on the polycarbonate filter. LPS-matured MDDCs (1.25 × 105; LPS) were added to the top chamber in the presence of the indicated stimuli: blocking anti-CD38 mAb [IB4 F(ab')2], agonistic anti-CD38 mAb (IB4), anti-CD31 mAb (Moon-1), 8-Br-cADPR, or irrelevant control mAbs [Ctr mAb, Ctr F(ab')2]. Results are the mean values ± SE of 5 independent experiments. The transendothelial migration of LPS-matured MDDCs represented 32.5% ± 4.5% of the cell input. *Statistically significant differences (P < .05) with respect to LPS-induced migration.](https://ash.silverchair-cdn.com/ash/content_public/journal/blood/107/6/10.1182_blood-2005-07-2913/4/zh80060692420001.jpeg?Expires=1730409665&Signature=tKUaEb1GtpBmkTn8ntQMtl22wGlQayqrkMUn9oTl07icg3kZaHhfWSA7CLIL42OZh5zG8fvs~g8oCCNevJo58MnHh0ypBeAYzGt5skR7oMsHH9hn51HCmLzmzblBbdlm1IsYuBkWMQhoBRYxZM59-He5tiNFiyZsBBc0lYz46K8JYcVVgLFDVPsviDA7b-tPvvhfMuD0Fz6MBXNHYXn2RdtqccueENOT4RrdxRQuIGRYhMBmYzo794t7BNQUjyLe~hpgj2M2PIaZYs9xolMHFyRrW1PrPyiao1Oc5bBjiA6ByBHnT3Jeq99FMIok4MMmC2LE86hqrtXA0F9GXQVnLg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
CD38 is involved in mMDDC chemotaxis and migration. Lymphoid organ–derived CCL21-driven chemotaxis (A) and transendothelial migration (B) of mMDDCs. (A) LPS-matured MDDCs (1.25 × 105; LPS) were added to the transwell upper chamber in the presence of the indicated stimuli: blocking anti-CD38 mAb (AT13/5), agonistic anti-CD38 mAbs (IB4 and AT2), anti-CD31 mAb (Moon-1), 8-Br-cADPR, or irrelevant control mAb (Ctr mAb). Results are expressed as percentage of migrated cells with respect to migration of LPS-matured MDDCs (28.7% ± 5.3% of the cell input) and are the mean values ± SE of 5 independent experiments. Statistically significant differences (P < .05) with respect to LPS-induced migration are indicated. (B) HPMEC-ST1.6R cells (4 × 105) were grown to confluence on the polycarbonate filter. LPS-matured MDDCs (1.25 × 105; LPS) were added to the top chamber in the presence of the indicated stimuli: blocking anti-CD38 mAb [IB4 F(ab')2], agonistic anti-CD38 mAb (IB4), anti-CD31 mAb (Moon-1), 8-Br-cADPR, or irrelevant control mAbs [Ctr mAb, Ctr F(ab')2]. Results are the mean values ± SE of 5 independent experiments. The transendothelial migration of LPS-matured MDDCs represented 32.5% ± 4.5% of the cell input. *Statistically significant differences (P < .05) with respect to LPS-induced migration.
